Changes in the nanoparticle uptake and distribution caused by an intramacrophagic parasitic infection
Source abstract
Abstract
-glycolic nanoparticles (PLGA NPs), as this parasitic infection produces morphological alterations in liver, spleen and bone marrow, organs highly involved in NP sequestration. The results showed that the magnitude of the effect was specific for each organ and type of NP. With the exception of the liver, the general trend was a decrease in NP organ and cellular uptake, mostly due to immune cell mobilization and/or weight organ gain, as vascular permeability was increased. Moreover, NPs redistributed among different phagocytic cells to adapt infection associated changes and cellular alterations. In the liver, it is noteworthy that only isolated Kuffer cells (KCs) captured NPs, whereas they were not taken up by KC forming granulomas. In the spleen, NPs redistributed from macrophages and dendritic cells towards B cells and inflammatory monocytes although they maintained their preferential accumulation in the marginal zone and red pulp. Comparatively, the infection rarely affected the NP cellular distribution in the bone marrow. NP cellular target changes in VL infection could affect their therapeutic efficacy and should be considered for more efficient drug delivery.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Research on Leishmaniasis Studies · Reproductive System and Pregnancy · Parasites and Host Interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
ISTUN Institute of Tropical Health, University of Navarra, Irunlarrea 1, 31008, Pamplona, Spain
Chemistry and Pharmaceutical Technology Department, University of Navarra, Irunlarrea 1, 31008, Pamplona, Spain
Navarra Institute for Health Research, IdisNA, Spain
Funding
Gobierno de Navarra · Universidad de Navarra · Fundación Caja Navarra
References (71)
Show source-provided references
1. WHO, Leishmaniasis , https://www.who.int/en/news-room/fact-sheets/detail/leishmaniasis , (accessed July 27, 2021 )
2. Burza · Lancet · 2018 · 392 · 95110.1016/S0140-6736(18)31204-2 ↗
3. J. J.Lauthier , The Leishmaniases: Old Neglected Tropical Diseases , ed. F. Bruschi , Springer , 2018
4. Murray · Int. J. Exp. Pathol. · 2001 · 82 · 24910.1046/j.1365-2613.2001.00199.x ↗
5. Stanley · Immunol. Cell Biol. · 2007 · 85 · 13810.1038/sj.icb7100011 ↗
6. Engwerda · Trends Parasitol. · 2004 · 20 · 52410.1016/j.pt.2004.08.009 ↗
7. Engwerda · Am. J. Pathol. · 2002 · 161 · 42910.1016/S0002-9440(10)64199-5 ↗
8. Poulaki · Microorganisms · 2021 · 9 · 75910.3390/microorganisms9040759 ↗
9. Cotterell · Infect. Immun. · 2000 · 68 · 184010.1128/IAI.68.4.1840-1848.2000 ↗
10. Abidin · PLoS Pathog. · 2017 · 13 · e100642210.1371/journal.ppat.1006422 ↗
11. Moghimi · J. Innate Immun. · 2012 · 4 · 50910.1159/000339153 ↗
12. Stone · Drugs · 2016 · 76 · 48510.1007/s40265-016-0538-7 ↗
13. Alves · Clin. Microbiol. Rev. · 2018 · 31 · e00048-1810.1128/CMR.00048-18 ↗
14. Wagh · Bioconjugate Chem. · 2012 · 23 · 98110.1021/bc200637h ↗
15. Tavares · Proc. Natl. Acad. Sci. U. S. A. · 2017 · 114 · E1087110.1073/pnas.1713390114 ↗
16. Wick · J. Visualized Exp. · 2018 · 139 · e57037
17. Tsoi · Nat. Mater. · 2016 · 15 · 121210.1038/nmat4718 ↗
18. Gershkovich · J. Antimicrob. Chemother. · 2010 · 65 · 53510.1093/jac/dkp465 ↗
19. Voak · Antimicrob. Agents Chemother. · 2017 · 61 · 0049710.1128/AAC.00497-17 ↗
20. Cataldi · Int. J. Mol. Sci. · 2017 · 18 · 124910.3390/ijms18061249 ↗
21. Meng · ACS Nano · 2018 · 12 · 645810.1021/acsnano.8b02881 ↗
22. Patonay · Appl. Spectrosc. · 2005 · 59 · 68210.1366/0003702053945976 ↗
23. Reisch · Small · 2016 · 12 · 196810.1002/smll.201503396 ↗
24. Texier · J. Biomed. Opt. · 2009 · 14 · 05400510.1117/1.3213606 ↗
25. Chu · Biomaterials · 2013 · 34 · 842410.1016/j.biomaterials.2013.07.038 ↗
26. Wei · Nanomedicine · 2018 · 13 · 149510.2217/nnm-2018-0040 ↗
27. Chen · Nanoscale · 2015 · 7 · 1586310.1039/C5NR03626G ↗
28. Park · Nanomedicine · 2016 · 12 · 136510.1016/j.nano.2016.01.013 ↗
29. Firdessa · Eur. J. Cell Biol. · 2014 · 93 · 32310.1016/j.ejcb.2014.08.001 ↗
30. O'Keeffe · PLoS One · 2019 · 14 · e021998510.1371/journal.pone.0219985 ↗
31. Zent · FEBS J. · 2017 · 284 · 102110.1111/febs.13961 ↗
32. Schulz · Sci. Rep. · 2019 · 9 · 192510.1038/s41598-018-38127-9 ↗
33. Saito · J. Controlled Release · 2019 · 300 · 18510.1016/j.jconrel.2019.02.025 ↗
34. Chu · ACS Nano · 2015 · 9 · 1180010.1021/acsnano.5b05583 ↗
35. Getts · Sci. Transl. Med. · 2014 · 6 · 219ra21710.1126/scitranslmed.3007563 ↗
36. Wang · Nat. Nanotechnol. · 2014 · 9 · 20410.1038/nnano.2014.17 ↗
37. Smith · Nat. Nanotechnol. · 2014 · 9 · 48110.1038/nnano.2014.62 ↗
38. Jones · J. Clin. Invest. · 2013 · 123 · 306110.1172/JCI66895 ↗
39. Weissleder · Nat. Mater. · 2014 · 13 · 12510.1038/nmat3780 ↗
40. Yang · J. Controlled Release · 2016 · 227 · 8210.1016/j.jconrel.2016.02.011 ↗
41. Dong · Theranostics · 2017 · 7 · 75110.7150/thno.18069 ↗
42. Fromen · ACS Nano · 2017 · 11 · 1079710.1021/acsnano.7b03190 ↗
43. Hidalgo · Trends Immunol. · 2019 · 40 · 58410.1016/j.it.2019.04.013 ↗
44. Hu · Curr. Drug Metab. · 2018 · 19 · 72310.2174/1389200219666171207120643 ↗
45. Fenaroli · ACS Nano · 2018 · 12 · 864610.1021/acsnano.8b04433 ↗
46. Fenaroli · ACS Nano · 2014 · 8 · 701410.1021/nn5019126 ↗
47. Elvevold · Am. J. Physiol.: Gastrointest. Liver Physiol. · 2008 · 294 · G39110.1152/ajpcell.00056.2007 ↗
48. Beattie · PLoS Pathog. · 2010 · 6 · e100080510.1371/journal.ppat.1000805 ↗
49. Kaye · Semin. Immunopathol. · 2016 · 38 · 24910.1007/s00281-015-0548-7 ↗
50. Kaye · Semin. Immunopathol. · 2020 · 42 · 24710.1007/s00281-020-00788-y ↗
51. Mandl · J. Controlled Release · 2019 · 314 · 9210.1016/j.jconrel.2019.09.020 ↗
52. de Melo · Front. Immunol. · 2020 · 11 · 65310.3389/fimmu.2020.00653 ↗
53. Terrazas · Sci. Rep. · 2017 · 7 · 1469310.1038/s41598-017-14935-3 ↗
54. Yurdakul · Am. J. Pathol. · 2011 · 179 · 2310.1016/j.ajpath.2011.03.009 ↗
55. Silva-Barrios · Cell Rep. · 2016 · 15 · 242710.1016/j.celrep.2016.05.028 ↗
56. Ergen · Biomaterials · 2017 · 114 · 10610.1016/j.biomaterials.2016.11.009 ↗
57. Preham · Front. Immunol. · 2018 · 9 · 295810.3389/fimmu.2018.02958 ↗
58. Musumeci · Acta Trop. · 1978 · 35 · 183
59. Ergen · Biomaterials · 2019 · 206 · 4910.1016/j.biomaterials.2019.03.025 ↗
60. Moghimi · Annu. Rev. Pharmacol. Toxicol. · 2012 · 52 · 48110.1146/annurev-pharmtox-010611-134623 ↗
61. Mitchell · Nat. Rev. Drug Discovery · 2021 · 20 · 10110.1038/s41573-020-0090-8 ↗
62. Alamo · Pharmaceutics · 2020 · 12 · 100410.3390/pharmaceutics12111004 ↗
63. Debie · Mol. Pharm. · 2017 · 14 · 114510.1021/acs.molpharmaceut.6b01053 ↗
64. Bertrand · Nat. Commun. · 2017 · 8 · 77710.1038/s41467-017-00600-w ↗
65. Cilliers · Mol. Pharm. · 2017 · 14 · 162310.1021/acs.molpharmaceut.6b01091 ↗
66. Abstiens · Soft Matter · 2019 · 15 · 70910.1039/C8SM02189A ↗
67. Bauknight · PLoS One · 2019 · 14 · e022491710.1371/journal.pone.0224917 ↗
68. Gershkovich · J. Antimicrob. Chemother. · 2009 · 64 · 10110.1093/jac/dkp140 ↗
69. Wijnant · Antimicrob. Agents Chemother. · 2018 · 62 · e02009
70. Hamill · Drugs · 2013 · 73 · 91910.1007/s40265-013-0069-4 ↗
71. Weissleder · Nat. Mater. · 2014 · 13 · 12510.1038/nmat3780 ↗